The Apple Watch SE is $80 off right now
The Watch SE easily found a place on our list of the best Apple smartwatches. Despite being the company's bare-bones model, it still offers plenty of bang for the buck. It can do crash detection, heart rate monitoring, emergency calling and more. There's a reason why we called it 'the best smartwatch for the money' in our official review.
It uses the same chip as the original Ultra and the Series 8, so the performance is on point. It's covered in durable Ion-X glass and offers 50 meters of water resistance. The screen isn't quite as bright as with the pricier models, but we still found the display to be 'crisp and easy to read.' The watch is also lightweight and comfortable.
There are some trade-offs here when compared to Apple's more extravagant smartwatches. The SE doesn't support the new Double Tap feature for Siri requests and it doesn't include a blood oxygen monitor or a temperature sensor. The final caveat? This watch came out in 2022, so a refresh is likely on the horizon.
Follow @EngadgetDeals on Twitter and subscribe to the Engadget Deals newsletter for the latest tech deals and buying advice.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
40 minutes ago
- Yahoo
Apple Supplier BIEL Crystal Unveils "Witch Cloak" Ultra-Hard Coating Smartphone Glass Cover
HONG KONG, Aug. 20, 2025 /PRNewswire/ -- BIEL Crystal, a key Apple supplier and global leader in smart device components, has launched its revolutionary ultra-hard coating smartphone glass cover – "Witch Cloak". This breakthrough cover glass is now featured on Honor's latest Magic V5 foldable smartphone. According to official Honor mobile phone data, devices equipped with Witch Cloak glass demonstrate: 10x improvement in drop resistance 15x enhancement in scratch prevention 3x increase in abrasion durability significantly reducing screen cracks and breakages from everyday impacts. About WITCH CLOAK ultra-hard coating The Witch Cloak ultra-hard coating glass utilizes a glass-ceramic substrate coated with precisely alternating layers of silicon nitride (SiN) and silicon oxynitride (SiON). BIEL Crystal offers customizable coating solutions ranging multilayer to meet specific durability requirements. About BIEL Crystal Founded in 1989, BIEL Crystal is a leading global provider of exterior structure and module solutions for smart devices. Our products are widely used in smart digital devices, smart wearable devices, AR/VR glasses and automotive industry. Our long-term cooperation customers include Apple, Samsung, Xiaomi, vivo, Meta, ByteDance, Tesla, Google and so on. With more than 30 years of technological innovation and excellent management, BIEL Crystal has become a large technology innovation group with 9 advanced production bases worldwide, with a total investment of over HK$42 billion, covering a total area of about 4.3 million square meters, employing more than 90,000 people and with an annual production capacity of 2.2 billion pieces. View original content to download multimedia: SOURCE BIEL Crystal Sign in to access your portfolio
CNBC
40 minutes ago
- CNBC
CNBC Daily Open: The U.S. tech-sell off extends to its second day — but don't let it ruin your summer
If you have any U.S. technology stocks in your portfolio (and let's face it, who doesn't?), you might want to look away. For the second day in a row, tech stocks dragged markets lower, with the Nasdaq Composite slipping 0.67%. Juggernauts such as Apple, Amazon and Alphabet were more meh-nificent than magnificent, falling more than 1%. Palantir — the standout S&P 500 stock, having more than doubled so far this year — spent its sixth consecutive day in the red and lost its place among a ranking of the 20 most valuable U.S. companies. While Palantir's slide was partly triggered by a report from short seller Andrew Left's Citron Research, which called the company "detached from fundamentals and analysis," there was no single trigger for the broader pullback. Investors could have been spooked by OpenAI CEO Sam Altman's caution about an AI bubble forming, although some analysts dispute that assertion. "In our view the tech bull cycle will be well intact at least for another 2-3 years," said Wall Street tech bull Dan Ives. Or it could be something benign, like traders locking in profits. "Tech stocks," said Carol Schleif, chief market strategist at BMO Private Wealth, "have had an incredibly strong run – with some up over 80% since the early April lows." Summer, after all, is far from over. Some investors might have just wanted to cash out for another round of margaritas. Fed officials divided over inflation and employment worries. Central bank governors generally agreed there were risks on both sides. But a couple — breaking from the majority — saw the labor market woes as more pressing, according to minutes of the Fed's July meeting. Trump likely to pick Kevin Hasset as next Fed Chair. The director of the National Economic Council firmly led the pack, according to a CNBC Fed Survey. However, respondents think the president "should" pick former Fed Governor Kevin Warsh. No new solar or wind power projects, Trump says. Renewable energy projects will no longer receive approval, Trump posted Wednesday on Truth Social. His comment comes after the administration already tightened federal permitting last month. Fourth day of losses for the S&P 500. Investors continued selling off technology stocks on Wednesday, with Palantir having its sixth straight losing day. The U.K.'s FTSE 100 closed at another high despite inflation in July coming in hotter than expected. [PRO] The Fed is expected to cut just as markets trade at highs. This is what tends to happen when both factors coincide, according to Goldman Sachs research. Trump has snapped up more than $100 million in bonds since taking office U.S. President Donald Trump has been on a multimillion-dollar bond-buying spree since taking office in January, investing in debt issued by local authorities, gas districts and major American corporations. Across 33 pages of filings with the U.S. Office of Government Ethics, or OGE, dated Aug. 12, the president outlined 690 transactions that have taken place since he took office. The documents were made public on Tuesday.
Yahoo
44 minutes ago
- Yahoo
Surf Bio Announces Peer-Reviewed Publication Demonstrating Feasibility of Subcutaneous Delivery of Ultra-Concentrated Biologics
Research conducted by Stanford University and published in Science Translational Medicine shows successful injection of protein formulations exceeding 500 mg/mL PALO ALTO, Calif., Aug. 20, 2025 /PRNewswire/ -- Surf Bio, a biopharmaceutical company transforming the delivery of antibodies and biologics, announced today that a peer-reviewed study conducted by researchers at Stanford University and published in Science Translational Medicine has demonstrated the feasibility of reformulating biologics for subcutaneous delivery at ultra-high concentrations. The study's lead author, Carolyn Jons, Ph.D., and collaborators reported that spray-dried microparticle formulations surpassed 500 mg/mL and were delivered through a standard 27-gauge needle at clinically relevant forces, marking a potential breakthrough in expanding access to infusion-only therapies. The paper, entitled, "Glassy Surfactants Enable Ultra-High Concentration Biologic Therapeutics," may be accessed via the following URL: "The research addresses one of the most persistent challenges in drug delivery: how to administer high-dose biologic therapies without the need for intravenous infusion," stated Dr. Jons. "Many existing protein-based therapies require hospital or clinic-based infusions due to their large volume, instability, or reconstitution requirements. This study describes a spray-drying process that converts protein formulations into microparticles suspended in a non-solvent liquid carrier, resulting in a stable, ready-to-inject solution that meets the viscosity and force thresholds for subcutaneous administration." "This research provides a critical foundation for our work at Surf Bio and highlights the significant potential of our SnapShot™ technology," said Bryan Mazlish, CEO of Surf Bio. "We're leveraging this licensed platform to help unlock subcutaneous administration for therapies that have historically required IV infusion. Our goal is to translate this innovation into ready-to-inject, patient-friendly formulations that reduce burden on the healthcare system while enabling self-administration at home." Importantly, the platform utilizes a polymer excipient that improves stability during spray drying and enhances the injectability of the final formulation. In preclinical models, these microparticles were shown to maintain protein activity and structure, achieving doses well beyond those currently accessible with drug products approved for subcutaneous delivery. The technology does not require any specialized delivery device and can be used with commercially available autoinjectors and standard fill-finish processes. About Surf Bio:Surf Bio is a biopharmaceutical company transforming the delivery of antibodies and biologics via its SnapShot™ technology platform. Powered by the Company's proprietary polymer, SnapShot enables the development of ultra-high concentration formulations of monoclonal antibodies (mAbs) and biologics that can be administered using a single, standard autoinjector shot. To date, in-vitro and in-vivo safety and efficacy data have demonstrated that SnapShot enables drug developers to produce very high concentration, subcutaneous formulations of novel mAbs and biologics. Surf Bio was launched by the founders of Bigfoot Biomedical and AGC to commercialize a breakthrough drug delivery technology developed in the Appel lab at Stanford University. For more information about Surf Bio, visit Contact for Surf Bio:Tiberend Strategic Advisors, Reissereiss@ View original content to download multimedia: SOURCE Surf Bio, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
